A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
← catalyst calendarSponsored by Bausch & Lomb Incorporated (industry) · BLCO — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
443actual
Sites
32
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-24 | actual | When the study began enrolling |
| Primary completion | 2026-05-28 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-28 | actual | The whole study's end, after follow-up |
| First posted | 2025-08-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Dry Eye Disease
Interventions
- Drug: Lifitegrast/Perfluorohexyloctane Fixed Dose Combination
- Drug: Lifitegrast
- Drug: Perfluorohexyloctane
- Drug: Vehicle
- Drug: Vehicle
- Drug: Vehicle
Primary outcome
what the primary-completion date above is the date OFTotal corneal fluorescein staining change from baseline
measured Baseline, day 29
Permalink · BLCO's whole pipeline · Catalyst calendar · Every registered study · What changed